A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS986165 in Adolescent Subjects with Moderate to Severe Plaque Psoriasis

CONDITION

Skin

GENDER

Both males and females

AGE GROUP

From 12

to 17 years

STATUS

Recruiting

This study will be a multi-center, randomized, double-blind, placebo controlled study, to evaluate the efficacy and safety of BMS-986165 in adolescent subjects ages 12 to < 18 years.

This study will consist of two parts and the study participation is approximately up to 66 weeks for each part. Both parts will be divided into the following periods: screening (up to 6 weeks), treatment (52 weeks), and safety follow-up at 4 weeks and 8 weeks.

CONTACT DETAILS

Clinical Trial Site: The Skin Hospital (Skin & Cancer Foundation Australia)
Phone Number: (02) 8651 2027 Email: clinicaltrials@skinhospital.edu.au Location: 121 Crown Street, Darlinghurst NSW, Australia
  • Hidden

Approved By: Bellberry              

Clinical Trial Registry Link: